Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia--Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual Disease
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (10) , 1719-1725
Abstract
Anti-B4-blocked ricin is an immunotoxin consisting of anti-B4 murine monoclonal antibody and "blocked ricin" toxin. The anti-B4 monoclonal antibody is directed against the CD19 antigen, which is expressed on B-lymphocytes. A phase II study of anti-B4 blocked ricin toxin in patients with B-cell chronic lymphocytic leukemia (CLL) with residual disease after chemotherapy was conducted. Eleven patients received anti-B4 blocked ricin at 30 μg/kg lean body mass (LBM) daily by continuous infusion for 7 days followed with repeat infusion administered at 14-day intervals. No patient achieved an objective response. The major reasons for failure to respond were the presence of adenopathy and residual marrow disease. Three patients achieved immunophenotypic response in marrow and peripheral blood. Three of 6 patients with rearranged IgH and/or Igκ were germline after anti-B4 blocked ricin. The median follow-up of surviving patients is 8.6 years. The median survival is 5.8 years (range, 0.0-8.8). All patients have pro...Keywords
This publication has 20 references indexed in Scilit:
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- Progress in CLL, chemotherapy, antibodies and transplantationBiomedicine & Pharmacotherapy, 2001
- Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood, 2001
- Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphomaCancer, 1998
- Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemiaThe Lancet, 1996
- Effect of cell arrangement and interstitial volume fraction on the diffusivity of monoclonal antibodies in tissueBiophysical Journal, 1993
- Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusionBlood, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958